下一代疗法比拼升级Infigratinib并非唯一挑战Vosoritide的选手，在ACH治疗赛道，多款下一代疗法正加速推进，从周剂注射到高选择性靶向，行业的研发比拼正不断升级，Vosoritide的垄断时代已进入倒计时。
[&:first-child]:overflow-hidden [&:first-child]:max-h-full"，更多细节参见heLLoword翻译官方下载
�@�L���̂��߁A���C�����X�C���t�H���̂悤�ɏ[�d��Bluetooth�ڑ��̈��芴�Ȃǂ��C�ɂ��邱�ƂȂ����p�\�B�V���������s�@�A�J�t�F�Ȃǂł̍��ƒ��Ɋ��p�����A���͂̃m�C�Y�}�������^�X�N�ɖv�����₷���Ȃ��B，更多细节参见WPS下载最新地址
It’s also worth noting that even if alternatives superior to agar were found, scientists are reluctant to abandon established protocols (even when microbiologists do use other jellies, they often still add agar to the mix, for example, to increase the gel strength of the solid media). As agar has been the standard gelling agent in microbiology for around 150 years, an enormous infrastructure of standardized methods, reference values, and quality control procedures has emerged around its specific properties. Switching to a different medium (even a superior one) means results may not be directly comparable to decades of published literature or to other laboratories’ findings.